Page 133 - Read Online

Page 8 of 20 Akinci et al. Vessel Plus 2021;5:56 https://dx.doi.org/10.20517/2574-1209.2021.20

Neutral ICH ICH SBP > 150 24 h Labetalol, 90 days 39 < 150 7.83 Within 2 h 36 < 180 8.54 (3.8- Within 2 h Perihemat Perihemat Perihemat
ADAPT [59 patients hydralazin (3.25- in 79% of 15.75) h in 100% oma oma oma
]
, e, 16.75) h patients of relative relative relative
2013 enalapril patients CBF CBF 0.86 CBF 0.89
± 0.12 ± 0.09
Supporte INTERAC ICH SBP 150- 6 h Labetalol, 90 days 1399 < 140 4 (2.9- Within 1h 1430 < 180 4.5 (3-7) - Death or 52% had 55.6%
[49]
d T-2 , patients 220 metoprolo 5.1) h in 33.4% h disability a poor had a
2013 l, of by mRS outcome poor
hydralazin patients (3-6) at event outcome
e, three event
phentola months
mine, post
nicardipin randomiza
e, tion
nimodipin
e,
nitroglyce
rin,
urapidil,
esmolol,
clonidine,
enalapril,
nitropruss
ide,
furosemid
e, and oral
agents
Supporte Gong et al. ICH SBP > 160 4 h Nitroglyce 14 days 60 130-140 2.24 ± 1 h 60 160-180 2.13 ± 1.05 1 h Hematom Hematom Hematom
[66,67]
d patients rin 1.23 h a a a
, expansion expansion expansion
2015 , edema : 5 : 14
volume, (8.33%) (23.33%)
serum NIHSS NIHSS
MMP-9 score: score:
level 6.28 ± 7.82 ±
3.68 4.28
Lower Higher
edema edema
volume volume
and serum and serum
MMP-9 MTP-9
levels levels
after 5 after 5
and 14 and 14
days days
Arguing/ ATACH- ICH SBP 180- 4.5 h Nicardipin 90 days 500 110-139 182.2 ± Within 2 h 500 140-179 184.7 ± Within 2 h Death or 38.7% 37.7%
[48,68]
against 2 , patients 240 e, 57.2 min in 87.8% 56.7 min in 99.2% disability had a had a
2016 labetalol, of of by mRS primary primary